Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: RNA base editor therapeutics - Beam Therapeutics

Next Previous
Search
Drug Profile

Research programme: RNA base editor therapeutics - Beam Therapeutics

Latest Information Update: 28 Jun 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Beam Therapeutics
  • Class Gene therapies
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Sickle cell anaemia

Most Recent Events

  • 28 Jun 2022 No recent reports of development identified for research development in Sickle-cell-anaemia in USA (Parenteral)
  • 12 Aug 2020 Beam Therapeutics and Boston Childrens Hospital agree to co-develop disease-specific therapies using base editing technology for sickle cell disease, paediatric leukaemias and other indications
  • 31 Oct 2019 Beam Therapeutics and Prime Medicine enter into an agreement for the development of prime editing technology for various purposes, including for the treatment of sickle cell disease

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top